NASDAQ:SLRX Salarius Pharmaceuticals (SLRX) Stock Price, News & Analysis → The asset beating inflation by 4x (From Colonial Metals) (Ad) Free SLRX Stock Alerts $0.50 -0.03 (-5.04%) (As of 04:28 PM ET) Add Compare Share Share Today's Range$0.49▼$0.5350-Day Range$0.45▼$0.6852-Week Range$0.43▼$2.31Volume20,106 shsAverage Volume92,577 shsMarket Capitalization$2.39 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Salarius Pharmaceuticals alerts: Email Address Ad Banyan Hill PublishingForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsIf you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)Watch my video for all of the details About Salarius Pharmaceuticals Stock (NASDAQ:SLRX)Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds and Cancer Prevention and Research Institute of Texas for product development activities. The company is headquartered in Houston, Texas.Read More SLRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SLRX Stock News HeadlinesMay 2, 2024 | americanbankingnews.comSalarius Pharmaceuticals (NASDAQ:SLRX) Stock Price Up 7.5%April 2, 2024 | finance.yahoo.comSLRX Pursues Important GoalMay 3, 2024 | Altimetry (Ad)Urgent Nvidia WarningCould Steve Job's 'Final Prophecy' Make You Rich? Just before he died, Steve Jobs issued a "Final Prophecy" that's now coming true... and making some people rich. In one recent 90-day stretch, 50 companies related to Jobs' "Final Prophecy" soared by 100% or more. What was Steve Jobs' last big prediction, and how can you get in on it? Professor Joel Litman explains everything... including the surprising group of stocks moving higher, and his No. 1 favorite stock in this space.March 27, 2024 | msn.comWall Street Set to Open Modestly Lower Monday Ahead of Housing, Inflation DataMarch 25, 2024 | msn.comWhy Salarius Pharmaceuticals Shares Are Trading Higher By Around 31%; Here Are 20 Stocks Moving PremarketMarch 23, 2024 | finanznachrichten.deSalarius Pharmaceuticals, Inc.: Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateMarch 22, 2024 | sfgate.comSalarius: Q4 Earnings SnapshotMarch 22, 2024 | globenewswire.comSalarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateMay 3, 2024 | Altimetry (Ad)Urgent Nvidia WarningCould Steve Job's 'Final Prophecy' Make You Rich? Just before he died, Steve Jobs issued a "Final Prophecy" that's now coming true... and making some people rich. In one recent 90-day stretch, 50 companies related to Jobs' "Final Prophecy" soared by 100% or more. What was Steve Jobs' last big prediction, and how can you get in on it? Professor Joel Litman explains everything... including the surprising group of stocks moving higher, and his No. 1 favorite stock in this space.March 5, 2024 | msn.comQuoin stock craters 47% on public offering after rallying in prior sessionMarch 4, 2024 | msn.comQuoin stock soars 60% on FDA update for ichthyosis drugFebruary 22, 2024 | markets.businessinsider.comSalarius Pharmaceuticals Implements Cost-savings MeasuresFebruary 22, 2024 | msn.comSalarius's CEO David Arthur steps downFebruary 22, 2024 | finance.yahoo.comSalarius Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing ExpensesFebruary 9, 2024 | uk.investing.comSalarius Pharmaceuticals Inc (SLRX)January 16, 2024 | finance.yahoo.comSalarius Pharmaceuticals Issued U.S. Patent for Next-Generation Targeted Protein DegradersJanuary 13, 2024 | wsj.comSquare Pharmaceuticals Ltd.January 3, 2024 | finance.yahoo.comInvestigator-initiated Phase 1/2 Clinical Trial Using Salarius Pharmaceuticals’ Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Resumes Patient EnrollmentNovember 10, 2023 | finance.yahoo.comSLRX Continues Work as it Seeks AlternativesNovember 8, 2023 | morningstar.comSalarius Pharmaceuticals Inc SLRXNovember 7, 2023 | finance.yahoo.comSalarius Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development ProgramAugust 10, 2023 | bizjournals.comSalarius Pharmaceuticals cuts half of workforce despite positive clinical developmentsAugust 10, 2023 | finance.yahoo.comSalarius Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides a Business UpdateAugust 9, 2023 | finance.yahoo.comSLRX Pursuing Strategic AlternativesJuly 11, 2023 | benzinga.comWatching Salarius Pharma; Zacks Small-Cap Research Sets $6.75 Price TargetJuly 11, 2023 | finance.yahoo.comSLRX Continues Cancer Fight with Phase I Trial ApprovalJuly 11, 2023 | marketwatch.comSalarius Pharmaceuticals Gets FDA Clearance for Lymphoma Drug ApplicationSee More Headlines Receive SLRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Salarius Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/22/2024Today5/03/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:SLRX CUSIPN/A CIK1615219 Webwww.salariuspharma.com Phone(832) 834-6992FaxN/AEmployees2Year Founded2011Profitability EPS (Most Recent Fiscal Year)($4.53) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-12,540,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-197.96% Return on Assets-135.23% Debt Debt-to-Equity RatioN/A Current Ratio5.02 Quick Ratio5.02 Sales & Book Value Annual Sales$1.84 million Price / Sales1.30 Cash FlowN/A Price / Cash FlowN/A Book Value$1.34 per share Price / Book0.37Miscellaneous Outstanding Shares4,780,000Free Float4,513,000Market Cap$2.39 million OptionableNot Optionable Beta0.95 Social Links 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. David J. Arthur M.B.A. (Age 61)CEO, President & Director Comp: $343.2kMr. Mark J. Rosenblum CPA (Age 71)Executive VP of Finance & CFO Key CompetitorsAllarity TherapeuticsNASDAQ:ALLRSonoma PharmaceuticalsNASDAQ:SNOAAltamira TherapeuticsNASDAQ:CYTOCohBarNASDAQ:CWBRCNS PharmaceuticalsNASDAQ:CNSPView All CompetitorsInstitutional OwnershipArmistice Capital LLCSold 137,000 shares on 2/13/2024Ownership: 2.234%View All Institutional Transactions SLRX Stock Analysis - Frequently Asked Questions Should I buy or sell Salarius Pharmaceuticals stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Salarius Pharmaceuticals in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" SLRX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SLRX, but not buy additional shares or sell existing shares. View SLRX analyst ratings or view top-rated stocks. How have SLRX shares performed in 2024? Salarius Pharmaceuticals' stock was trading at $0.65 at the beginning of the year. Since then, SLRX stock has decreased by 22.9% and is now trading at $0.5010. View the best growth stocks for 2024 here. Are investors shorting Salarius Pharmaceuticals? Salarius Pharmaceuticals saw a drop in short interest in April. As of April 15th, there was short interest totaling 115,600 shares, a drop of 57.0% from the March 31st total of 268,900 shares. Based on an average daily volume of 111,900 shares, the days-to-cover ratio is presently 1.0 days. Approximately 2.6% of the shares of the stock are sold short. View Salarius Pharmaceuticals' Short Interest. When is Salarius Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our SLRX earnings forecast. How were Salarius Pharmaceuticals' earnings last quarter? Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) announced its quarterly earnings data on Friday, March, 22nd. The company reported ($0.22) EPS for the quarter, topping analysts' consensus estimates of ($1.01) by $0.79. What ETF holds Salarius Pharmaceuticals' stock? Horizon Kinetics Medical ETF holds 31,094 shares of SLRX stock, representing 0.09% of its portfolio. When did Salarius Pharmaceuticals' stock split? Shares of Salarius Pharmaceuticals reverse split on the morning of Monday, October 17th 2022. The 1-25 reverse split was announced on Monday, October 17th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Monday, October 17th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. What other stocks do shareholders of Salarius Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Salarius Pharmaceuticals investors own include Evofem Biosciences (EVFM), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Arbutus Biopharma (ABUS), Fulcrum Therapeutics (FULC), Allena Pharmaceuticals (ALNA), Biocept (BIOC), DURECT (DRRX), Dynavax Technologies (DVAX) and TG Therapeutics (TGTX). How do I buy shares of Salarius Pharmaceuticals? Shares of SLRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SLRX) was last updated on 5/3/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldUrgent Nvidia WarningAltimetryCould Your Accounts Be Frozen?Allegiance GoldDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThe Gold Grab of the CenturyColonial MetalsForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the MarketsREAD THIS – If You Missed Out On The AI BoomBanyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Salarius Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.